Abstract
Cerebrospinal fluid (CSF) is being analyzed for the diagnosis of a variety of neurological diseases. Among the methods employed, metabolomics and proteomics are increasingly gaining popularity. At present, sensitivity and, in particular, specificity are limited in CSF metabolomics by nuclear magnetic resonance (NMR) spectroscopy. Nonetheless, progress is being made by studying more and more well-defined and homogeneous patient cohorts. This review starts off with a brief overview of classical CSF analysis in multiple sclerosis (MS), followed by a description of NMR spectroscopy in general metabolic CSF analysis. The subsequent sections focus on metabolomic profiling of CSF by NMR spectroscopy in MS and other neurological disorders. Currently existing results are reviewed and compared, and the potential and limits of this approach are discussed. In addition, several methodological questions are addressed, and the prospects for future developments are briefly outlined.
Keywords: Multiple sclerosis (MS), metabolomics, cerebrospinal fluid (CSF), nuclear magnetic resonance spectroscopy (NMR, MRS), neurological diseases, Cerebrospinal fluid, proteomics, homogeneous patient cohorts, multiple sclerosis, neurological disorders, biomarkers, qualitative and quantitative protein analysis, drug targets
Current Pharmaceutical Biotechnology
Title: Metabolic Profiling in Multiple Sclerosis and Other Disorders by Quantitative Analysis of Cerebrospinal Fluid Using Nuclear Magnetic Resonance Spectroscopy
Volume: 12 Issue: 7
Author(s): N. W. Lutz and P. J. Cozzone
Affiliation:
Keywords: Multiple sclerosis (MS), metabolomics, cerebrospinal fluid (CSF), nuclear magnetic resonance spectroscopy (NMR, MRS), neurological diseases, Cerebrospinal fluid, proteomics, homogeneous patient cohorts, multiple sclerosis, neurological disorders, biomarkers, qualitative and quantitative protein analysis, drug targets
Abstract: Cerebrospinal fluid (CSF) is being analyzed for the diagnosis of a variety of neurological diseases. Among the methods employed, metabolomics and proteomics are increasingly gaining popularity. At present, sensitivity and, in particular, specificity are limited in CSF metabolomics by nuclear magnetic resonance (NMR) spectroscopy. Nonetheless, progress is being made by studying more and more well-defined and homogeneous patient cohorts. This review starts off with a brief overview of classical CSF analysis in multiple sclerosis (MS), followed by a description of NMR spectroscopy in general metabolic CSF analysis. The subsequent sections focus on metabolomic profiling of CSF by NMR spectroscopy in MS and other neurological disorders. Currently existing results are reviewed and compared, and the potential and limits of this approach are discussed. In addition, several methodological questions are addressed, and the prospects for future developments are briefly outlined.
Export Options
About this article
Cite this article as:
W. Lutz N. and J. Cozzone P., Metabolic Profiling in Multiple Sclerosis and Other Disorders by Quantitative Analysis of Cerebrospinal Fluid Using Nuclear Magnetic Resonance Spectroscopy, Current Pharmaceutical Biotechnology 2011; 12 (7) . https://dx.doi.org/10.2174/138920111795909122
DOI https://dx.doi.org/10.2174/138920111795909122 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Alzheimers Disease and Intelligence
Current Alzheimer Research Coffee: A Rich Source of Antimicrobial and Antiviral Compounds
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Nicotinamide: Oversight of Metabolic Dysfunction Through SIRT1, mTOR, and Clock Genes
Current Neurovascular Research Editorial [Hot Topic: Amyloid-Associated Disease Mechanisms in Alzheimers Disease (Guest Editor: Jeroen J.M. Hoozemans)]
Current Drug Targets - CNS & Neurological Disorders Multi-Target Profile of Oleocanthal, An Extra-Virgin Olive Oil Component
Current Bioactive Compounds Biochemical Markers for Brain Injury Monitoring in Children with or without Congenital Heart Diseases
CNS & Neurological Disorders - Drug Targets Level of Knowledge About Alzheimer's Disease Among Nursing Staff in Suzhou and its Influencing Factors
Current Alzheimer Research Subtype Classification by Polymerase and Gag Genes of HIV-1 Iranian Sequences Registered in the NCBI GenBank
Current Proteomics Potential Use of Nanomedicine for Drug Delivery Across the Blood-Brain Barrier in Healthy and Diseased Brain
CNS & Neurological Disorders - Drug Targets Treatment of Large Vessel Vasculitis
Current Immunology Reviews (Discontinued) RNA G-Quadruplex: The New Potential Targets for Therapy
Current Topics in Medicinal Chemistry Pharmacological Benefits of Active Components of Natural Products Against Traumatic Brain Injury - A Review
Current Pharmacogenomics and Personalized Medicine DHA–lysophospholipid Production
Current Organic Chemistry Neuron-Specific Mitochondrial DNA Deletion Levels in Sporadic Alzheimer´s Disease
Current Alzheimer Research The Role of Type 2 Fibroblast Growth Factor in Periodontal Therapy
Current Drug Targets Genetic Contributors to Frontotemporal Lobar Degeneration: Beyond Monogenic Disease
Mini-Reviews in Medicinal Chemistry An Integrated Approach to Fragment-Based Lead Generation:Philosophy, Strategy and Case Studies from AstraZenecas Drug Discovery Programmes
Current Topics in Medicinal Chemistry Disruption of Calcium Homeostasis in the Pathogenesis of Alzheimers Disease and Other Conformational Diseases
Current Alzheimer Research 5-HT1 Receptors
Current Drug Targets - CNS & Neurological Disorders Relevance of Nutritional Antioxidants in Metabolic Syndrome, Ageing and Cancer: Potential for Therapeutic Targeting
Infectious Disorders - Drug Targets